FreeTheAI

Regeneron Upgraded to Buy as Wall Street Underestimates Dupixent Growth

BullishMedium impact
REGN$778.36 3.35%SNY$39.77 1.66%

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) received a rating upgrade to Buy from Neutral, accompanied by a new price target of $978. The updated valuation target implies roughly 30% upside potential from recent closing levels. Shares of the biotech firm rose 3.35% to $778.40 following the action.

The bullish call stems from Wall Street underestimating the long-term potential of blockbuster treatment Dupixent (dupilumab), which is co-developed alongside Sanofi SA (NASDAQ:SNY). Analysts project Dupixent revenue could hit $16 billion by 2035, significantly higher than the broader market consensus of $13 billion.

Key milestones lie ahead as Regeneron advances four next-generation Dupixent candidates designed to extend market exclusivity past 2031. Initial clinical trial data for the lead candidate is expected early next year, with Phase 3 testing targeted for the second half of 2027. Early-stage trials for the remaining three candidates are scheduled to begin in early 2027.

Key points

  • Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was upgraded to Buy with a target price of $978.
  • Analysts forecast 2035 Dupixent revenue at $16 billion, exceeding the $13 billion consensus estimate.
  • Four next-generation Dupixent candidates are in development to extend product exclusivity.
  • Data from the first candidate readout is expected early next year before entering Phase 3 in late 2027.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

Why was Regeneron Pharmaceuticals stock upgraded?

The stock was upgraded due to overlooked potential in its next-generation Dupixent pipeline and the likelihood of extending market exclusivity beyond 2031.

What is the target price for Regeneron stock?

The target price was set at $978 per share, offering around 30% upside from recent closing prices.

What are the timeline expectations for next-generation Dupixent?

The first candidate could release study data early next year and start Phase 3 trials in late 2027. Early-stage trials for three other candidates are planned for early 2027.